Tibulizumab is a tetravalent bispecific monoclonal antibody that acts as an antagonist against B-cell activating factor (BAFF) and IL-17A, with Kd values of 60 pM and 14 pM, respectively, and is suitable for research into autoimmune diseases.

IL-17A:14 pM (Kd), BAFF (mouse):340 nM (Kd), BAFF:60 pM (Kd)

Tibulizumab can bind to mouse BAFF with a KD value of 340 nM, but does not bind to mouse IL-17; its KD values for binding to cynomolgus monkey BAFF and IL-17 are 26.8 pM and 19 pM, respectively . In HT-29 cells, this antibody can concentration-dependently antagonize IL-17-induced CXCL1 secretion with an IC50 of 2.00 nM; in T1165 cells, it can concentration-dependently inhibit BAFF-induced cell proliferation with an IC50 of 0.064 nM, and can simultaneously bind to and block both BAFF and IL-17 [1].

When administered via intraperitoneal injection at 660 μg per mouse or subcutaneous injection at 66 μg per mouse, Tibulizumab can effectively antagonize the biological effects mediated by human BAFF and IL-17 in mice . In cynomolgus monkeys, administration of Tibulizumab via intravenous injection (0.3, 1, 5, 20 mg/kg) or subcutaneous injection (5 mg/kg) can inhibit B cell development and survival, maintain functional stability in the circulation, and extend the half-life [1].

Human

Monoclonal, Bispecific

Unconjugated